ArticleFrontiers in endocrinology2026
Ocular manifestations and immunological profiles of thyroid eye disease with lacrimal gland enlargement.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid eye disease (TED) is a prevalent autoimmune inflammatory condition in patients diagnosed with Graves' disease (GD). The lacrimal glands are implicated as an additional target organ of autoimmune reactions in TED, alongside orbital connective tissues. However, the underlying pathogenesis of lacrimal gland enlargement in TED and its associated symptoms and effective therapeutic strategies remain to be elucidated. This study aimed to investigate the ocular manifestations and immunological profiles of TED with lacrimal gland enlargement. Methods: This study collected patients diagnosed with TED, divided into the enlarged lacrimal gland (ELG) and the normal lacrimal gland (NLG) groups based on magnetic resonance imaging (MRI) measurement. Ocular manifestations, thyroid function tests, and immunological examinations of the peripheral blood were systematically compared between the two groups. Results: 123 TED patients (NLG: ELG = 36: 87) were enrolled in this study. Patients in the ELG group exhibited worse proptosis, decreased tear film break-up time (TBUT), and increased Schirmer I test values, compared to the NLG group (P < 0.05), with no statistical difference in clinical activity score (CAS). Lacrimal gland enlargement in TED was accompanied by an elevation in thyroid peroxidase antibody (TPO-Ab) levels. Moreover, the proportions of CD8 Conclusions: TED patients with enlarged lacrimal glands exhibited worse proptosis, unstable tear film, and excessive tearing. TPO-Ab and Treg cells were positively correlated with lacrimal gland enlargement in TED. Furthermore, Treg cell frequency emerged as a predictive biomarker for lacrimal gland involvement in TED patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.